- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03578887
A Cohort Study of Weight Loss and Gliosis
April 7, 2023 updated by: Ellen Schur, MD, MS, University of Washington
A Twin Study of Obesity Pathogenesis Using fMRI
Patients and clinicians need better options to prevent the weight regain that almost universally follows a weight loss intervention.
In lay terms, a new, higher "set point" seems to occur after people gain weight.
Evidence from some research studies reinforces these observations, showing that processes of energy homeostasis vigorously defend the higher level of adiposity for years, if not permanently.
Only bariatric surgery appears to "re-set" to a lower level of adiposity.
No clear mechanism has been elucidated to date that explains these phenomena.
The current proposal endeavors to address this crucial scientific gap by translating preclinical data into human studies testing novel mechanistic hypotheses.
Prior studies in rodents show that a high-fat diet causes inflammation and a cellular response, known as gliosis, within hypothalamic regions regulating energy balance and glucose homeostasis.
Evidence further suggests that gliosis might play a pathogenic role in obesity and type 2 diabetes mellitus (T2D) because its development precedes weight gain and impaired glucose homeostasis and its inhibition improves metabolic health.
Importantly, gliosis is detectable in mice and humans by magnetic resonance imaging (MRI).
Using MRI, the investigators discovered the first evidence of gliosis in obese humans and went on to show associations of gliosis with insulin resistance in humans, independent of the level of adiposity.
New findings suggest that people with T2D have more extensive gliosis than is seen in nondiabetic obese subjects.
Further findings reveal that gliosis improves, but is not completely reversed, 8 mo.
after Roux-en-Y gastric bypass (RYGB) surgery in T2D patients.
It remains unknown whether gliosis improves similarly when weight loss occurs by lifestyle change or if the efficacy and durability of weight loss via bariatric surgery is partially explained by its ability to reverse gliosis via an as yet unknown mechanism of action.
We therefore propose three studies in humans to discover 1) if hypothalamic gliosis is reversed by a standard behavioral weight loss intervention, 2) if the extent of gliosis predicts successful weight loss during, or weight regain after, behavioral weight loss, and 3) the time course of improvement in gliosis after RYGB and the relation of its improvement to the short- and long-term efficacy of RYGB.
Future research would define dietary, environmental, or other risk factors for the development of hypothalamic gliosis in humans.
Achieving a better understanding of the role of the brain in obesity and its treatment could open new avenues for research, intervention, and prevention.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
112
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Roz De Leon
- Phone Number: 206-616-6360
- Email: uwwebs@uw.edu
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington - South Lake Union
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 64 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Aged 25-64 years
- Behavioral Weight Loss (BWL) & Surgical Weight Loss (SWL) (Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy): BMI 30- <56 kg/m²
- RYGB and Sleeve Gastrectomy: eligible for RYGB or Sleeve Gastrectomy and not undergoing revision or reoperation
- Healthy Weight Controls (HWC): BMI 18.5-24.9 kg/m²
Exclusion Criteria:
- Poorly controlled hypertension or coronary artery disease, or chronic disease (e.g. cancer, multiple sclerosis, autoimmune disease, rheumatic disease) Blood Pressure > 160/100 mmHG Heart Rate > 110 bpm
- Chronic kidney disease (GFR <60 mL/min/1.73 m2),
- Presence of cirrhosis (Nonalcoholic Fatty Liver Disease (NALFD)/Nonalcoholic Steatohepatitis (NASH) are acceptable),
- Previous or planned (during the study period) obesity treatment with surgery (planned surgery ok for the SWL group) or a weight loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed > 1 year before screening, (2) lap banding, if the band has been removed > 1 year before screening, (3) intragastric balloon, if the balloon has been removed > 1 year before screening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening,
- A1c > 8.5% in Bariatric group; A1c ≥ 6.5% for BWL and HWC groups,
- Current use of insulin (insulin ok for Surgical Weight Loss group, also called SWL), DPP-4 inhibitors, thiazolidinediones or medications known to alter metabolic function (e.g. atypical antipsychotics, corticosteroids),
- Pregnancy or breastfeeding,
- MRI contraindications (e.g. implanted metal, claustrophobia), or unable to have MRI or fit in MRI scanner
- Current smoking/daily use of nicotine containing products (cigarettes, e-cigarettes, vaping or other nicotine containing products) or heavy alcohol use,
- Weight >450 pounds (iDXA limit),
- Weight-reduced from lifetime maximum weight by >16%,
- Weight not stable over past 3 months (±10%),
- T2D (for BWL or HWC),
- Inability to participate in a weight loss program (BWL)
- History of eating disorder or current eating disorder, currently enrolled in a weight loss program (ok for the SWL group provided weight stability and lifetime weight-reduced maximum conditions are met) or taking medications to lose weight
- Severe food allergies
- Any condition that the study physician determines to be unsafe for participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lifestyle Cohort
Participants Undergoing Behavioral Weight Loss Program
|
Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
|
Active Comparator: Surgical Cohort
Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
|
Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
|
No Intervention: Healthy Weight Control Cohort
Healthy Weight Controls With No Intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Weight Loss
Time Frame: During 6 Month Behavioral Weight Loss Program
|
During 6 Month Behavioral Weight Loss Program
|
Weight Regain
Time Frame: During 12-Month Follow-Up After Intervention
|
During 12-Month Follow-Up After Intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ellen Schur, MD, MS, University of Washington
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2019
Primary Completion (Anticipated)
June 30, 2024
Study Completion (Anticipated)
June 30, 2024
Study Registration Dates
First Submitted
June 25, 2018
First Submitted That Met QC Criteria
June 25, 2018
First Posted (Actual)
July 6, 2018
Study Record Updates
Last Update Posted (Actual)
April 11, 2023
Last Update Submitted That Met QC Criteria
April 7, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00002978
- 2R01DK089036-06 (U.S. NIH Grant/Contract)
- 1K24HL144917-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Gliosis, Weight-Loss
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and...Active, not recruitingObesity, ChildhoodUnited States
-
University of California, San FranciscoCompletedClinically Severe Obesity | Obesity Recidivism | Inadequate Initial Weight Loss | Poor Weight Loss | Persistent Obesity | Refractory Obesity | Intractable ObesityUnited States
-
University of California, San FranciscoCompletedInadequate Initial Weight Loss | Persistent Clinically Severe ObesityUnited States
-
University of California, San FranciscoCompletedClinically Severe Obesity | Inadequate Weight Loss | Obesity RecidivismUnited States
-
Loma Linda UniversityNovo Nordisk A/SRecruitingObesity | Weight Loss | Overweight or Obesity | Weight, Body | Obesity; Drug | Weight Loss TrajectoryUnited States
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Virginia Commonwealth UniversityChildren's Hospital FoundationCompletedPediatric Obesity | Impact of Parent Intervention on Adolescent Weight LossUnited States
-
University of Colorado, DenverCompletedDietary Habits | Overweight and Obesity | Weight Loss MaintenanceUnited States
-
Drexel UniversityUniversity of PennsylvaniaCompletedObesity | Overweight | Weight Loss MaintenanceUnited States
-
University of HawaiiQueen's Medical Center; I Ola Lahui, Inc.; Ke Ola Mamo; Queen Lili'uokalani Children... and other collaboratorsCompletedObesity | Overweight | Weight Loss | Weight Loss MaintenanceUnited States
Clinical Trials on Behavioral Weight Loss Program
-
University of North Carolina, Chapel HillCompletedOverweight and ObesityUnited States
-
Rush University Medical CenterCompleted
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Williams CollegeTemple UniversityRecruitingObesity | Weight LossUnited States
-
East Carolina UniversityCompleted
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingObesityUnited States
-
Florida State UniversityCompleted
-
University of PittsburghNational Institutes of Health (NIH)Completed
-
The Miriam HospitalUnknownObesity | OverweightUnited States
-
National Institute of Diabetes and Digestive and...Completed